Login to Your Account



N30 Is Seeking the Road to Cystic Fibrosis Therapy, Without VCs

By Marie Powers
Staff Writer

Monday, May 6, 2013
newco_news_resized.jpg

Armed with a novel technology and a new target – a class of disease modifying therapies that preserve intracellular S-nitrosoglutathione (GSNO), a regulator of organ repair, regeneration and healing – N30 Pharmaceuticals Inc. has quietly evolved from a 2007 start-up into a development-stage biotech with 30 employees.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription